This compound, also known as Tepotinib, is a selective small-molecule inhibitor of the mesenchymal-epithelial transition factor (MET) receptor tyrosine kinase. It is approved for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. By binding to the MET kinase domain, it inhibits phosphorylation of MET and downstream signaling, thereby suppressing tumor growth, proliferation, and metastasis in MET-driven cancers. Clinical studies have demonstrated its efficacy and safety in targeted patient populations, positioning it as a key precision therapy in oncology.